|Dr. Guy Chamberland M.Sc., Master Herbal||Co-Founder, CEO, Chief Regulatory Officer & Director||447.65k||N/A||1962|
|Mr. Steeve Néron||Chief Commercial Officer||181.55k||N/A||N/A|
|Mr. André Rancourt B.Sc.||Co-Founder||N/A||N/A||N/A|
|Dr. Melanie Edna Mary Kelly Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Jennifer McCaughey||VP of Investor Relations||N/A||N/A||N/A|
|Ms. Dania Scott B.Sc.||Sr. VP of Commercial Strategy||N/A||N/A||N/A|
|Ms. Aurelia De Pauw||Sr. VP of Clinical Programs & Medical Affairs||N/A||N/A||N/A|
|Mr. Richard Giguere||Chief Exec. Officer of Tetra Natural Health Inc.||N/A||N/A||N/A|
|Randy Ringuette||Project Director & Member of Advisory Board||N/A||N/A||N/A|
|Mr. Chris MacLean||Chief Operating Officer of Tetra Natural Health||N/A||N/A||N/A|
Tetra Bio-Pharma Inc., a biopharmaceutical company, engages in the discovery and development of cannabinoid-derived drugs for inflammation, pain, ophthalmology, and oncology. The company develops PLENITUDE to treat cancer-related pain in advanced cancer patients; REBORN for the treatment of breakthrough cancer pain; Reduvo for chemotherapy-induced nausea and vomiting; ARDS-003 for the treatment of sepsis and prevention of acute respiratory distress syndrome; and SERENITY to treat cancer cachexia. It also develops PPP003 for painful dry eye and uveitis pain; and HCC011 for hepatocellular carcinoma. The company is headquartered in Orléans, Canada.
Tetra Bio-Pharma Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.